Preventive and therapeutic potential of p38α-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes

被引:15
作者
Medicherla, Satyanarayana [1 ]
Protter, Andrew A. [1 ]
Ma, Jing Ying [1 ]
Mangadu, Ruban [1 ]
Almirez, Ramona [1 ]
Koppelman, Bruce [1 ]
Kerr, Irene [1 ]
Navas, Tony A. [1 ]
Movius, Fabiola [1 ]
Reddy, Mamatha [1 ]
Liu, Yu-Wang [1 ]
Luedtke, Gregory [1 ]
Perumattam, John [1 ]
Mavunkel, Babu [1 ]
Dugar, Sundeep [1 ]
Schreiner, George F. [1 ]
机构
[1] Scios Nova Inc, Fremont, CA 94555 USA
关键词
D O I
10.1124/jpet.105.097857
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mitogen-activated protein kinases (MAPKs) and heat shock proteins (HSPs) are ubiquitous proteins that function within T cells in both normal and stress-related pathophysiological states, including type 1 diabetes. The nonobese diabetic (NOD) mouse spontaneously develops T cell-mediated autoimmune pancreatic beta cell destruction that is similar to type 1 diabetes in humans. Because p38 MAPKs have been shown to modulate T cell function, we studied the effects of a p38 alpha MAPK-selective inhibitor, indole-5-carboxamide (SD-169), on the development and progression of type 1 diabetes in the NOD mouse. In preventive treatment studies, SD-169 significantly reduced p38 and HSP60 expression in T cells of the pancreatic beta islets. Following treatment, the incidence of diabetes as determined by blood glucose levels was significantly lower, and immunohistochemistry of pancreatic beta islet tissue demonstrated significant reduction in CD5(+) T cell infiltration in the SD-169 treatment group as compared with untreated NOD mice. In therapeutic studies using mildly and moderately hyperglycemic NOD mice, SD-169 treatment lowered blood glucose and improved glucose homeostasis. Furthermore, following cessation of SD-169 treatment, NOD mice showed significant arrest of diabetes. In conclusion, we report that this p38 alpha-selective inhibitor prevents the development and progression of diabetes in NOD mice by inhibiting T cell infiltration and activation, thereby preserving beta cell mass via inhibition of the p38 MAPK signaling pathway. These results have bearing on current prophylactic and therapeutic protocols using p38 alpha-selective inhibitors in the prediabetic period for children at high risk of type 1 diabetes, in the honeymoon period, and for adults with latent autoimmune diabetes.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 37 条
[21]   PREVENTIVE EFFECTS OF CYCLOSPORINE ON DIABETES IN NOD MICE [J].
MORI, Y ;
SUKO, M ;
OKUDAIRA, H ;
MATSUBA, I ;
TSURUOKA, A ;
SASAKI, A ;
YOKOYAMA, H ;
TANASE, T ;
SHIDA, T ;
NISHIMURA, M ;
TERADA, E ;
IKEDA, Y .
DIABETOLOGIA, 1986, 29 (04) :244-247
[22]   Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653 [J].
Nishikawa, M ;
Myoui, A ;
Tomita, T ;
Takahi, K ;
Nampei, A ;
Yoshikawa, H .
ARTHRITIS AND RHEUMATISM, 2003, 48 (09) :2670-2681
[23]   PREDICTION AND PREVENTION OF IDDM - 1991 [J].
PALMER, JP ;
MCCULLOCH, DK .
DIABETES, 1991, 40 (08) :943-947
[24]   Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis [J].
Prakken, BJ ;
Roord, S ;
Ronaghy, A ;
Wauben, M ;
Albani, S ;
van Eden, W .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2003, 25 (01) :47-63
[25]   JNK and p38 MAP kinases in CD4+ and CD8+ T cells [J].
Rincón, M ;
Pedraza-Alva, G .
IMMUNOLOGICAL REVIEWS, 2003, 192 (01) :131-142
[26]   Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway [J].
Rincón, M ;
Enslen, H ;
Raingeaud, J ;
Recht, M ;
Zapton, T ;
Su, MSS ;
Penix, LA ;
Davis, RJ ;
Flavell, RA .
EMBO JOURNAL, 1998, 17 (10) :2817-2829
[27]   MAP-kinase signaling pathways in T cells [J].
Rincón, M .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (03) :339-345
[28]   Reversal of established autoimmune diabetes by restoration of endogenous β cell function [J].
Ryu, S ;
Kodama, S ;
Ryu, K ;
Schoenfeld, DA ;
Faustman, DL .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (01) :63-72
[29]  
Schäfer C, 2000, J GASTROENTEROL, V35, P1
[30]  
Schafer PH, 1999, J IMMUNOL, V162, P7110